Clinical Research Directory
Browse clinical research sites, groups, and studies.
225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women
Sponsor: Vietnam Military Medical University
Summary
This randomized controlled trial will compare two starting doses of follicle-stimulating hormone (FSH), 225 IU and 300 IU, during progestin-primed ovarian stimulation (PPOS) in women undergoing in vitro fertilization (IVF) who have a good reproductive prognosis. Participants will be randomly assigned to receive either 225 IU or 300 IU of FSH at the start of ovarian stimulation. The study will evaluate whether the starting FSH dose affects oocyte and embryo outcomes, with blastocyst formation as the primary outcome. Other outcomes will include oocyte morphology, fertilization, embryo development, and embryo quality. The findings may help determine an appropriate starting FSH dose for women with a good prognosis undergoing IVF using the PPOS protocol.
Official title: A Randomized Controlled Trial Comparing 225 IU Versus 300 IU Starting Doses of Follicle-Stimulating Hormone in Progestin-Primed Ovarian Stimulation for Women With Good Prognosis
Key Details
Gender
FEMALE
Age Range
18 Years - 34 Years
Study Type
INTERVENTIONAL
Enrollment
380
Start Date
2026-08-15
Completion Date
2029-08-31
Last Updated
2026-08-19
Healthy Volunteers
No
Interventions
Follitropin Alfa (Follitrope)
Follicle-stimulating hormone (FSH) is administered by subcutaneous injection as the gonadotropin for ovarian stimulation in a progestin-primed ovarian stimulation (PPOS) protocol. Participants are randomized to receive either 225 IU or 300 IU of FSH daily according to their assigned study arm, and the assigned dose is maintained unchanged throughout the ovarian stimulation period.
Locations (1)
An Sinh Hospital
Ho Chi Minh City, Ho Chi Minh City, Vietnam